JP2015522581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522581A5 JP2015522581A5 JP2015519155A JP2015519155A JP2015522581A5 JP 2015522581 A5 JP2015522581 A5 JP 2015522581A5 JP 2015519155 A JP2015519155 A JP 2015519155A JP 2015519155 A JP2015519155 A JP 2015519155A JP 2015522581 A5 JP2015522581 A5 JP 2015522581A5
- Authority
- JP
- Japan
- Prior art keywords
- hcmv
- membrane protein
- protein complex
- recombinant nucleic
- glycoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668975P | 2012-07-06 | 2012-07-06 | |
| US61/668,975 | 2012-07-06 | ||
| US201361770257P | 2013-02-27 | 2013-02-27 | |
| US61/770,257 | 2013-02-27 | ||
| PCT/EP2013/063750 WO2014005959A1 (en) | 2012-07-06 | 2013-06-29 | Complexes of cytomegalovirus proteins |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017149179A Division JP2017192400A (ja) | 2012-07-06 | 2017-08-01 | サイトメガロウイルスタンパク質の複合体 |
| JP2017149178A Division JP2017192399A (ja) | 2012-07-06 | 2017-08-01 | サイトメガロウイルスタンパク質の複合体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015522581A JP2015522581A (ja) | 2015-08-06 |
| JP2015522581A5 true JP2015522581A5 (enExample) | 2016-07-14 |
Family
ID=48783208
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519155A Pending JP2015522581A (ja) | 2012-07-06 | 2013-06-29 | サイトメガロウイルスタンパク質の複合体 |
| JP2017149179A Pending JP2017192400A (ja) | 2012-07-06 | 2017-08-01 | サイトメガロウイルスタンパク質の複合体 |
| JP2017149178A Pending JP2017192399A (ja) | 2012-07-06 | 2017-08-01 | サイトメガロウイルスタンパク質の複合体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017149179A Pending JP2017192400A (ja) | 2012-07-06 | 2017-08-01 | サイトメガロウイルスタンパク質の複合体 |
| JP2017149178A Pending JP2017192399A (ja) | 2012-07-06 | 2017-08-01 | サイトメガロウイルスタンパク質の複合体 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9683022B2 (enExample) |
| EP (1) | EP2869843B1 (enExample) |
| JP (3) | JP2015522581A (enExample) |
| KR (1) | KR20150031322A (enExample) |
| CN (1) | CN104853771A (enExample) |
| AU (1) | AU2013286093B2 (enExample) |
| CA (1) | CA2878344A1 (enExample) |
| ES (1) | ES2753138T3 (enExample) |
| GB (1) | GB2513768B (enExample) |
| HK (1) | HK1210037A1 (enExample) |
| IL (1) | IL236261A0 (enExample) |
| IN (1) | IN2014KN02929A (enExample) |
| MX (2) | MX355469B (enExample) |
| RU (1) | RU2015103891A (enExample) |
| SG (1) | SG11201408328VA (enExample) |
| WO (1) | WO2014005959A1 (enExample) |
| ZA (1) | ZA201409364B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2513768B (en) | 2012-07-06 | 2015-04-15 | Novartis Ag | Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins |
| ES2719720T3 (es) | 2012-07-27 | 2019-07-12 | Hope City | Una vacuna de MVA para la administración de un complejo de UL128 y para prevenir la infección por CMV |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| DK3077519T3 (en) * | 2013-12-03 | 2021-06-14 | Hookipa Biotech Gmbh | Cmv-vacciner |
| WO2015161926A1 (en) * | 2014-04-23 | 2015-10-29 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| WO2015165480A1 (en) * | 2014-04-30 | 2015-11-05 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| WO2015170287A1 (en) * | 2014-05-08 | 2015-11-12 | Redvax Gmbh | Means and methods for treating cmv |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
| EP3048114A1 (en) * | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| EP3047856A1 (en) * | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
| EP3347045A4 (en) | 2015-09-10 | 2019-08-28 | City of Hope | MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR |
| CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2017123652A1 (en) | 2016-01-11 | 2017-07-20 | Verndari, Inc. | Microneedle compositions and methods of using same |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
| CA3050914A1 (en) * | 2017-01-27 | 2018-08-02 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccine compositions of herpesvirus envelope protein combinations to induce immune response |
| CN110603262A (zh) | 2017-04-04 | 2019-12-20 | 华盛顿大学 | 显示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途 |
| EP3612550B1 (en) | 2017-04-19 | 2025-06-18 | GlaxoSmithKline Biologicals S.A. | Modified cytomegalovirus proteins and stabilized complexes |
| US11174322B2 (en) * | 2017-07-24 | 2021-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies and peptides to treat HCMV related diseases |
| AU2018306614B2 (en) | 2017-07-28 | 2024-08-29 | Janssen Vaccines & Prevention B.V. | Methods and compositions for heterologous repRNA immunizations |
| AU2018331874B2 (en) | 2017-09-13 | 2022-06-02 | Sanofi Pasteur | Human cytomegalovirus immunogenic composition |
| AU2019228551B2 (en) | 2018-02-28 | 2025-07-24 | University Of Washington | Self-assembling nanostructure vaccines |
| JP7575096B2 (ja) | 2018-05-04 | 2024-10-29 | スパイバイオテック・リミテッド | ワクチン組成物 |
| MX2021004273A (es) | 2018-10-17 | 2021-12-10 | Glaxosmithkline Biologicals Sa | Proteinas de citomegalovirus modificadas y complejos estabilizados. |
| KR102609106B1 (ko) | 2018-12-10 | 2023-12-05 | 케이엠 바이올로직스 가부시키가이샤 | 사이토메갈로바이러스의 선천성 감염을 예방 또는 치료하기 위한 백신 |
| US11629172B2 (en) * | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| EP4004018A1 (en) | 2019-07-24 | 2022-06-01 | GlaxoSmithKline Biologicals SA | Modified human cytomegalovirus proteins |
| EP4163378A4 (en) | 2020-06-09 | 2024-03-13 | KM Biologics Co., Ltd. | Fusion protein of pentamer and gb of cytomegalovirus, and vaccine containing said fusion protein |
| US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| JP2023547197A (ja) | 2020-10-28 | 2023-11-09 | サノフィ・パスツール | Ｔｌｒ４アゴニストを含有するリポソーム、その製造および使用 |
| CA3211449A1 (en) * | 2021-02-24 | 2022-09-01 | Pfizer Inc. | Novel druggable regions in the human cytomegalovirus glycoprotein b polypeptide and methods of use thereof |
| WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1201757A3 (en) | 1988-12-22 | 2002-09-11 | Genentech, Inc. | Method for preparing water soluble polypeptides |
| HU218717B (hu) | 1989-03-17 | 2000-11-28 | E. I. Du Pont De Nemours And Co. | Nukleinsav-termelést fokozó növényi eredetű génfragmentek és eljárás előállításukra |
| EP0541721A4 (en) | 1990-08-02 | 1993-12-29 | Chiron Corporation | Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system |
| US5474914A (en) | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
| US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
| US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
| US5815900A (en) | 1995-03-06 | 1998-10-06 | Matsushita Electric Industrial Co., Ltd. | Method of manufacturing a surface acoustic wave module |
| US20040228842A1 (en) * | 2003-02-27 | 2004-11-18 | Shan Lu | Compositions and methods for cytomegalovirus treatment |
| EP3031469B1 (en) | 2006-06-07 | 2023-08-23 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| US7947274B2 (en) * | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
| US9439960B2 (en) | 2007-10-10 | 2016-09-13 | The Trustees Of Princeton University | Cytomegalovirus vaccines and methods of production |
| SG178954A1 (en) | 2009-09-02 | 2012-04-27 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
| US9089537B2 (en) * | 2010-02-26 | 2015-07-28 | The Trustees Of The University Of Pennslyvania | Subunit vaccines for herpes viruses and methods of use |
| NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
| RS54489B1 (sr) | 2010-07-06 | 2016-06-30 | Glaxosmithkline Biologicals Sa | Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk |
| WO2012015211A2 (ko) | 2010-07-30 | 2012-02-02 | 주식회사종근당 | 사이클로스포린 에이 함유 점안제 조성물 |
| EP2614072A4 (en) * | 2010-09-09 | 2014-03-19 | Univ Virginia Commonwealth | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| EP3520813B1 (en) | 2010-10-11 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| WO2012106377A2 (en) | 2011-01-31 | 2012-08-09 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
| EP3508219A1 (en) | 2011-07-06 | 2019-07-10 | GlaxoSmithKline Biologicals S.A. | Self-replicating rna prime - protein boost vaccines |
| EP3456316A1 (en) * | 2011-07-06 | 2019-03-20 | GlaxoSmithKline Biologicals S.A. | Cationic oil-in-water emulsions |
| US20140255472A1 (en) * | 2011-08-31 | 2014-09-11 | Andrew Geall | Pegylated liposomes for delivery of immunogen-encoding rna |
| GB2513768B (en) | 2012-07-06 | 2015-04-15 | Novartis Ag | Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
-
2013
- 2013-06-29 GB GB1413863.0A patent/GB2513768B/en active Active
- 2013-06-29 US US14/410,461 patent/US9683022B2/en active Active
- 2013-06-29 RU RU2015103891A patent/RU2015103891A/ru not_active Application Discontinuation
- 2013-06-29 CA CA2878344A patent/CA2878344A1/en not_active Abandoned
- 2013-06-29 CN CN201380036145.0A patent/CN104853771A/zh active Pending
- 2013-06-29 JP JP2015519155A patent/JP2015522581A/ja active Pending
- 2013-06-29 KR KR1020157002267A patent/KR20150031322A/ko not_active Withdrawn
- 2013-06-29 MX MX2014015496A patent/MX355469B/es active IP Right Grant
- 2013-06-29 MX MX2018000675A patent/MX378747B/es unknown
- 2013-06-29 ES ES13736518T patent/ES2753138T3/es active Active
- 2013-06-29 EP EP13736518.5A patent/EP2869843B1/en active Active
- 2013-06-29 WO PCT/EP2013/063750 patent/WO2014005959A1/en not_active Ceased
- 2013-06-29 AU AU2013286093A patent/AU2013286093B2/en not_active Ceased
- 2013-06-29 HK HK15110880.5A patent/HK1210037A1/xx unknown
- 2013-06-29 IN IN2929KON2014 patent/IN2014KN02929A/en unknown
- 2013-06-29 SG SG11201408328VA patent/SG11201408328VA/en unknown
-
2014
- 2014-12-15 IL IL236261A patent/IL236261A0/en unknown
- 2014-12-18 ZA ZA2014/09364A patent/ZA201409364B/en unknown
-
2017
- 2017-05-16 US US15/596,066 patent/US10287322B2/en active Active
- 2017-08-01 JP JP2017149179A patent/JP2017192400A/ja active Pending
- 2017-08-01 JP JP2017149178A patent/JP2017192399A/ja active Pending
-
2019
- 2019-03-25 US US16/363,127 patent/US20190211064A1/en not_active Abandoned
-
2021
- 2021-12-15 US US17/551,867 patent/US20220106364A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522581A5 (enExample) | ||
| RU2015103891A (ru) | Комплексы белков цитомегаловируса | |
| JP7613685B2 (ja) | 新規ｒｓｖ ｒｎａ分子及びワクチン接種用組成物 | |
| RU2733834C1 (ru) | Искусственный ген EctoS_SC2, кодирующий эктодомен гликопротеина S коронавируса SARS-CoV-2 с C-концевым тримеризующим доменом, рекомбинантная плазмида pStem-rVSV-EctoS_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-EctoS_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2 | |
| JP2023551982A (ja) | マルチシストロン性ｒｎａワクチン及びその使用 | |
| KR20070086344A (ko) | 탠덤 전사 유닛을 갖는 재조합 인플루엔자 벡터 | |
| NZ514132A (en) | Stable recombinant influenza viruses free of helper viruses | |
| JP2011182797A5 (enExample) | ||
| JP2019530466A5 (enExample) | ||
| JP2010530245A5 (enExample) | ||
| JP2017522907A5 (enExample) | ||
| CN103088049A (zh) | 日本脑炎病毒sa14-14-2株基于dna的感染性克隆、其构建方法及应用 | |
| CN118086288B (zh) | 多顺反子的自放大rna及制备方法 | |
| CN105396143A (zh) | 埃博拉病毒特异性的miRNA以及通过miRNA抑制埃博拉病毒的方法 | |
| JP2025169275A5 (enExample) | ||
| JP6944692B2 (ja) | ボルナウイルスベクター及びその利用 | |
| CN107201370A (zh) | 一种dna分子与重组病毒及它们的制备方法和用途 | |
| Macnaughton et al. | HDV RNA replication: ancient relic or primer? | |
| CN102286465B (zh) | 一种抑制口蹄疫病毒增殖的猪ifitm3基因及构建方法和应用 | |
| CN103966259B (zh) | 一种基于J亚群禽白血病病毒gag基因保守序列的siRNA重组干扰载体及其制备方法和应用 | |
| CN119144620B (zh) | 呼吸道合胞病毒mRNA疫苗及其制备方法和应用 | |
| CN105132459A (zh) | 人类ptx3重组蛋白的制备方法及应用 | |
| CN113876809B (zh) | 一种表达TgMIF蛋白的巨噬细胞在制备治疗肝纤维化药物中的应用 | |
| AU2024269492A1 (en) | Vaccine compositions | |
| US6616929B1 (en) | Swine vesicular disease virus expression vectors |